2022
DOI: 10.1016/j.jchromb.2022.123354
|View full text |Cite
|
Sign up to set email alerts
|

Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(13 citation statements)
references
References 15 publications
0
12
0
Order By: Relevance
“…was clinically used since 1957 [41], at first in the treatment of fungal infections. The majority bioanalytical assays of amphotericin B in various matrices used for human PK studies were detected using conventional ultraviolet (UV) detection that were more prominent before mass spectrometry (MS) detection [44,79,81,[84][85][86][87][88][89][90] was standardized. There are multiple formulations for amphotericin B, including amphotericin B lipid complex (ABLC), liposomal amphotericin B (L-AmB), amphotericin B colloidal dispersion (ABCD), and amphotericin B deoxycholate.…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…was clinically used since 1957 [41], at first in the treatment of fungal infections. The majority bioanalytical assays of amphotericin B in various matrices used for human PK studies were detected using conventional ultraviolet (UV) detection that were more prominent before mass spectrometry (MS) detection [44,79,81,[84][85][86][87][88][89][90] was standardized. There are multiple formulations for amphotericin B, including amphotericin B lipid complex (ABLC), liposomal amphotericin B (L-AmB), amphotericin B colloidal dispersion (ABCD), and amphotericin B deoxycholate.…”
Section: Resultsmentioning
confidence: 99%
“…Considering future target site antileishmanial PK studies the development and validation of bioanalytical methods for the quantification of antileishmanial drugs in human skin tissue (CL and PKDL), spleen, liver, and bone marrow (VL), and PMBCs (leishmaniasis in general) will gain prominence. Quantification in skin tissue was to date only published for amphotericin B [90], miltefosine [37], and pentavalent antimonials [163] and is expected to contribute to future antileishmanial target site PK studies in CL and PKDL patients. Quantification in liver was described for pentavalent antimonials [151,156].…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations